Payment overview · 2025
General Payments
$354.10
17 reported records · 9 companies
Healthcare provider profile · identity verified
Michael Stewart Comer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WEST COLUMBIA, SC · NPI 1699155119
Verified facts
What the public records show
CMS Open Payments records show Michael Stewart Comer, M.D. received $354.10 in general payments during 2025 across 17 reported records.
Dexcom, Inc. accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $96.26 | 27.2% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $51.39 | 14.5% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $50.91 | 14.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.75 | 13.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.62 | 11.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.68 | 5.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.41 | 4.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.52 | 4.4% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $13.56 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $354.10 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $96.26 | 4 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $50.91 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.75 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $31.36 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 503 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 89 |
| Gabapentin | Gabapentin | 315 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 82 |
| Omeprazole | Omeprazole | 261 | 73 |
| Losartan Potassium | Losartan Potassium | 227 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 78 |
| Metformin Hcl | Metformin Hcl | 187 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 59 |
| Lisinopril | Lisinopril | 179 | 53 |
| Furosemide | Furosemide | 172 | 50 |
| Alprazolam | Alprazolam | 171 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 42 |
| Trazodone Hcl | Trazodone Hcl | 159 | 39 |
| Meloxicam | Meloxicam | 151 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 27 |
| Tramadol Hcl | Tramadol Hcl | 110 | 41 |
| Prednisone | Prednisone | 107 | 85 |
| Sertraline Hcl | Sertraline Hcl | 103 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 25 |
| Pregabalin | Pregabalin | 97 | 16 |
| Simvastatin | Simvastatin | 88 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 18 |
| Ozempic | Semaglutide | 83 | 16 |
| Diazepam | Diazepam | 82 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 33 |
| Famotidine | Famotidine | 73 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 54 |
| Lorazepam | Lorazepam | 71 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 14 |
| Jardiance | Empagliflozin | 68 | 19 |
| Montelukast Sodium | Montelukast Sodium | 66 | 21 |
| Clonazepam | Clonazepam | 64 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 19 |
| Carvedilol | Carvedilol | 61 | 18 |
| Allopurinol | Allopurinol | 58 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 18 |
| Eliquis | Apixaban | 50 | 15 |
| Metformin Hcl Er | Metformin Hcl | 49 | 18 |
| Glipizide Er | Glipizide | 48 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 17 |
| Azithromycin | Azithromycin | 45 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 12 |
| Meclizine Hcl | Meclizine Hcl | 40 | 19 |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Potassium Chloride | Potassium Chloride | 38 | 14 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | 13 |
| Bupropion Xl | Bupropion Hcl | 36 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 21 |
| Alendronate Sodium | Alendronate Sodium | 31 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 15 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 14 |
| Colchicine | Colchicine | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 16 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 14 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Albendazole | Albendazole | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $354.10 · 17 records | Dexcom, Inc. | CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, Dexcom G6 Transmitter, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, Heplisav-B, INJECTAFER, JARDIANCE, OTEZLA, REPATHA, VRAYLAR, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error